1,189 results on '"Pusztai, L."'
Search Results
2. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3. Temperature dependent network stability in simple alcohols and pure water: the evolution of Laplace spectra
4. Topological descriptors and Laplace spectra in simple hydrogen bonded systems
5. Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
6. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
7. Proteins in solution: Fractal surfaces in solutions
8. On the composition dependence of thermodynamic, dynamic and dielectric properties of water-methanol model mixtures. Molecular dynamics simulation results
9. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
10. Reverse Monte Carlo modelling: the two distinct routes of calculating the experimental structure factor
11. Comparison of the TIP4P-2005, SWM4-DP and BK3 interaction potentials of liquid water with respect to their consistency with neutron and X-ray diffraction data of pure water
12. Temperature dependent network stability in simple alcohols and pure water: The evolution of Laplace spectra
13. An independent, general method for checking consistency between diffraction data and partial radial distribution functions derived from them: the example of liquid water
14. Immunological differences between primary and metastatic breast cancer
15. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
16. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
17. P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy
18. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
19. P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)
20. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
21. Radiotherapy Use and Locoregional Recurrence Rates on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer
22. Neutron Scattering Methods in Chemistry
23. 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
24. 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial
25. Structural properties of chalcogenide glasses and the isocoordination rule: Disentangling effects from chemistry and network topology
26. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer
27. Development of Pharmacogenomic Predictors for Preoperative Chemotherapy of Breast Cancer
28. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
29. 2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients
30. Reverse Monte Carlo Analyses of Diffraction Data on Molecular Liquids
31. Reverse Monte Carlo Modelling of Diffraction Data : Structural Studies of Amorphous Ices
32. A containerless study of short-range order in high-temperature Fe–Si–Al–Ca–Mg–Cr–Cu–Ni oxide systems
33. Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets
34. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
35. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
36. On the hydration structure of LiCl aqueous solutions: A Reverse Monte Carlo based combination of diffraction data and Molecular Dynamics simulations
37. Ink4a/Arf−/− and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f− quiescent cells
38. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
39. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
40. 259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
41. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
42. LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)
43. LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
44. Triple-negative breast cancer—current status and future directions
45. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
46. Molecular liquid TiCl 4 and VCl 4: Two substances, one structure?
47. The Structure of Molten Salts
48. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
49. The prognostic impact of age in patients with triple-negative breast cancer
50. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.